HIGH-DOSE NALOXONE FORMULATION

The USPTO published patent application US20260091030A1 for high-dose Naloxone formulations designed to treat ultra-potent synthetic opioid overdose. Invented by Gita Shankar and Suresh Potharaju, the formulation comprises naloxone hydrochloride with preservatives, buffering agents, and tonicity modifiers. The application was filed September 1, 2023, and published April 2, 2026.

Pridopidine for ALS Treatment

USPTO published patent application US20260091028A1 by Prilenia Neurotherapeutics Ltd. for a method of treating amyotrophic lateral sclerosis (ALS) using pridopidine. The application claims therapeutic use of pridopidine or a pharmaceutically acceptable salt for human subjects afflicted with ALS. Application No. 19391284 was filed on 2025-11-17.

Stilbene Derivatives as AHR Regulators with Improved Photostability

The USPTO published patent application US20260091027A1 for stilbene derivatives serving as aryl hydrocarbon receptor (AHR) regulators with improved photostability over the marketed drug Benvitimod. The application, filed September 19, 2023 under Application No. 19113670, covers compounds of formula I-1, their stereoisomers, salts, and prodrugs, along with preparation methods for gram-to-kilogram scale synthesis.

Methods of Treating Inflammatory Diseases with Formula I and II Compounds

The USPTO published patent application US20260091026A1 covering compounds of Formula (I) and Formula (II), and their use in treating inflammatory diseases. The application was filed December 5, 2025, and published April 2, 2026, naming inventors Robert Joseph Moreau, Naomi S. Rajapaksa, David C. Tully, and others. The claimed subject matter includes novel compounds, pharmaceutical compositions, and methods of treatment for inflammatory diseases and disorders.

Markers for the Diagnosis of Biochemical Recurrence in Prostate Cancer

USPTO published patent application US20260092922A1 for biomarkers and diagnostic methods related to prostate cancer biochemical recurrence (BCR). The application (No. 19207308, filed May 13, 2025) includes 9 inventors and covers methods for detecting BCR biomarkers, compositions, and diagnostic kits. This is a routine patent publication with no new regulatory requirements.

Electroacupuncture vs Sham for Recurrent Lower UTI Prevention in Women

ClinicalTrials.gov registered a randomized controlled trial (NCT07507851) comparing electroacupuncture to sham treatment for prevention of recurrent lower urinary tract infections in women. The single-center trial is conducted as an RCT design. No compliance obligations are created by this registration.

Methylprednisolone Evaluation in Hepatic Surgery

ClinicalTrials.gov registered a new clinical trial (NCT07507643) evaluating methylprednisolone administration in patients undergoing liver surgery (hepatectomy). The randomized controlled study aims to assess perioperative outcomes including liver function recovery and inflammatory response. Healthcare institutions conducting hepatic surgery research are the primary affected parties.

Pfizer Pharmacokinetics Study PF-07328948 in Healthy Male Adults

The National Library of Medicine registered Pfizer Study NCT07508228 on ClinicalTrials.gov, a Phase 1 pharmacokinetics trial evaluating PF-07328948 in healthy male adults. The study is listed with standard enrollment parameters and investigator information for public disclosure.

Technology-based hand rehabilitation older adults study

The National Library of Medicine's ClinicalTrials.gov registered a new clinical study (NCT07507279) titled 'Technology-based hand rehabilitation older adults study'. This randomized controlled trial will evaluate technology-based interventions for improving hand function in older adult populations.

Endoscopy Timing in Antiplatelet Patients With GI Bleeding

ClinicalTrials.gov registered a new observational study (NCT07507162) examining optimal endoscopy timing for patients on antiplatelet therapy presenting with gastrointestinal bleeding. The study is registered as an information collection activity without stated funding source.